Founded in 2000, Galectin Therapeutics Inc. (GALT) is a biotechnology company based in Norcross, Georgia, United States. This company, listed on the NASDAQ exchange, is involved in conducting critical research and development in the healthcare industry, focusing on therapeutics that can fight chronic diseases and cancer.
Galectin Therapeutics emphasizes research on galectin proteins, carbohydrate-binding proteins in our bodies, which play a considerable role in controlling inflammation, fibrosis, and even the growth of tumors. It has its research on various types of diseases, including fibrotic diseases and cancer. GALT applies its deep knowledge in complex carbohydrate chemistry and galectin science to develop promising therapies for patients with few treatment options.
The company’s signature product is the belapectin (previously known as GR-MD-02), a compound that targets galectin-3. It is currently the most advanced drug in the company’s pipeline and is being studied for its potential in treating non-alcoholic steatohepatitis (NASH) with cirrhosis, a severe form of non-alcoholic fatty liver disease. This product would bring value to millions of patients who often have to resort to liver transplants.
Galectin Therapeutics is also exploring belapectin’s ability to improve outcomes for cancer patients, given the significant role galectin-3 plays in tumor angiogenesis, the process by which cancerous tumors access blood supply to fuel their growth. It is an exciting avenue in cancer treatment as it seeks to thwart tumor growth by inhibiting its access to blood supply.
Notably, Galectin Therapeutics collaborates with top-tier academic medical research centers, ensuring access to world-class expertise and resources, enhancing its drug development efforts. These collaborations have brought the company considerable recognition and established it as a leading player in researching and developing therapeutics based on galectin proteins.
Galectin Therapeutics Inc. may still be a small cap biotech company, but it is one with significant potential given the innovative work that they are doing. Despite not yet having a product on the market, Galectin's ongoing research into the medical applications of galectin proteins, the cutting-edge nature of their work, and their dedication to addressing severe medical conditions make it an intriguing company in the biotech sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Galectin Therapeutics (NASDAQ:GALT) stock recently surpassed its 200-day moving average, reaching $4.02 before closing at $3.96. The company reported a quarterly loss of $0.14 per share, missing analyst estimates, and insiders have sold over 82,000 shares in the last three months. Analyst sentiment remains mixed, with an average "Hold" rating and an $11.00 consensus price target.
Galectin Therapeutics (NASDAQ:GALT) stock recently crossed above its 200-day moving average, trading at $3.91 with a 200-day average of $3.15. Analyst sentiment for GALT is mixed with a "Hold" consensus and an average price target of $11.00, despite the company reporting a wider-than-expected quarterly loss and recent insider stock sales.
Galectin Therapeutics (NASDAQ: GALT) announced its management will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The presentation is scheduled for September 14th at 11:30 AM ET and will include one-on-one meetings with investors. The company focuses on developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3 protein.
Galectin Therapeutics (NASDAQ:GALT) has attracted market attention after its shares moved above the two-hundred-day moving average, signaling stronger technical momentum. However, this momentum is contrasted by weaker-than-expected quarterly financial results and divided analyst sentiment. The company's future depends heavily on its clinical pipeline, particularly the progress of its lead candidate, belapectin, for liver disease, which remains crucial for long-term valuation despite short-term technical improvements.
Galectin Therapeutics (NASDAQ:GALT) shares recently crossed above their 200-day moving average, reaching $4.60 before closing at $4.35, significantly higher than the $3.10 average. Analyst sentiment is mixed, with a consensus "Hold" rating despite HC Wainwright maintaining a Buy rating and an $11 price target. The company missed its latest quarterly EPS estimates, reporting a $0.14 loss against an expected $0.09 loss, and saw insider selling of 89,594 shares, though insiders still hold 52.6% of the company.
Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer therapies. Despite the widening loss, Wall Street analysts maintain a positive outlook with 4 buy ratings and 1 hold rating, acknowledging the significant capital required for clinical-stage drug development.